India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

Sun Pharmaceutical Industries Ltd. closed 14.19% short of its 52-week high of 1,960.20 rupees, which the company reached on ...

Sun Pharmaceutical Industries Ltd. closed 15.15% short of its 52-week high of 1,960.20 rupees, which the company achieved on ...

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

The latest inspection comes 2 1/2 years after the agency allowed Sun Pharma to keep shipping some drugs to Americans even after banning the factory from the U.S. market because of quality problems.

A Sun Pharmaceutical plant in India that has been repeatedly cited by the FDA for serious quality control issues failed ...

The market needs to reclaim and sustain above the 20-day EMA to witness a further northward journey in the upcoming sessions.

LEQSELVI has shown rapid results in clinical trials, with one-third of patients regaining nearly full scalp hair by Week 24.

Sun Pharma settles litigation with Incyte, gains license for alopecia treatment, launches LEQSELVI tablet in the US.

Sun Pharma settles litigation with Incyte over Leqselvi, launches product for severe alopecia areata treatment in the US.

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...